{"id":398151,"date":"2020-12-11T08:03:33","date_gmt":"2020-12-11T13:03:33","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398151"},"modified":"2020-12-11T08:03:33","modified_gmt":"2020-12-11T13:03:33","slug":"alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/","title":{"rendered":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors<\/b><\/p>\n<p>SEATTLE&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAlpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine\u2019s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy.\n<\/p>\n<p>\n\u201cI\u2019m delighted to welcome Natasha to Alpine Immune Sciences\u2019 Board at this important moment in our company\u2019s history, as we build on our strategic partnership with AbbVie and leverage Alpine\u2019s financial strength to further advance our development pipeline,\u201d said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. \u201cI look forward to benefiting from Natasha\u2019s extensive experience and acumen as we oversee the next stages of Alpine\u2019s growth to the benefit of Alpiners, shareholders and patients alike.\u201d\n<\/p>\n<p>\nMs. Hernday currently serves as Executive Vice President, Corporate Development and as a member of the Executive Committee for the publicly traded biotechnology company Seagen, Inc. (NASDAQ: SGEN). Since joining Seagen in 2011, Ms. Hernday has built and led the business development team responsible for licensing deals, acquisitions and strategic alliances. From 1994 through 2010, after starting her career in molecular and mammalian cell biology, Ms. Hernday served in various roles of increasing responsibility at Amgen Inc., including as Director, Mergers &amp; Acquisitions and as Director, Out-Partnering. She also serves on the board of directors of Xoma Corp. (NASDAQ: XOMA) and PDL BioPharma, Inc. (NASDAQ: PDLI), and on the Knight Campus External Advisory Board for the University of Oregon.\n<\/p>\n<p>\nMs. Hernday received her BA in microbiology from the University of California at Santa Barbara and MBA from Pepperdine University.\n<\/p>\n<p>\nConcurrent with Ms. Hernday joining Alpine\u2019s Board of Directors, the company also announced that Paul Sekhri will be stepping down as a director of the company. Mr. Sekhri has served on Alpine\u2019s Board of Directors since February 2016.\n<\/p>\n<p>\nMitchell H. Gold commented, \u201cOn behalf of the Board and Alpine\u2019s executive team, I would like to thank Paul for the service he has provided to the company and wish him well in any and all future endeavors.\u201d\n<\/p>\n<p><b>About Alpine Immune Sciences, Inc. <\/b><\/p>\n<p>\nAlpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is creating multifunctional immunotherapies via unique protein engineering technologies designed to improve patients\u2019 lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alpineimmunesciences.com&amp;esheet=52346806&amp;newsitemid=20201211005057&amp;lan=en-US&amp;anchor=www.alpineimmunesciences.com&amp;index=1&amp;md5=04396ba349ae868ec4aa1440fa22cf66\">www.alpineimmunesciences.com<\/a>. Follow <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAlpineImmuneSci&amp;esheet=52346806&amp;newsitemid=20201211005057&amp;lan=en-US&amp;anchor=%40AlpineImmuneSci&amp;index=2&amp;md5=53d38c84520724f20b5c30c2e4f95fa0\">@AlpineImmuneSci<\/a> on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAlpineImmuneSci&amp;esheet=52346806&amp;newsitemid=20201211005057&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=84f11e5d47fe9690d226bece92cbb75a\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Falpine-immune-sciences%2F&amp;esheet=52346806&amp;newsitemid=20201211005057&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=f90c89ec9c8e65035144f6653bfe5bde\">LinkedIn<\/a>.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our platform technology and potential therapies, the future development plans and commercial potential of our product candidates, the progress and potential of our other ongoing development programs, and our ability to successfully develop and achieve milestones in our development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201cintend,\u201d and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations; our discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of our product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.\n<\/p>\n<p>\n\u201cSecreted Immunomodulatory Proteins\u201d, \u201cSIP\u201d, \u201cTransmembrane Immunomodulatory Protein,\u201d \u201cTIP,\u201d \u201cVariant Ig Domain,\u201d \u201cvIgD\u201d and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201211005057\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201211005057\/en\/<\/a><\/span><\/p>\n<p>\nPaul Rickey<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>Alpine Immune Sciences, Inc.<br \/>\n<br \/>206-788-4545<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@alpineimmunesciences.com\">ir@alpineimmunesciences.com<\/a><\/p>\n<p>\nLaurence Watts<br \/>\n<br \/>Managing Director<br \/>\n<br \/>Gilmartin Group, LLC.<br \/>\n<br \/>619-916-7620<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:laurence@gilmartinir.com\">laurence@gilmartinir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Washington<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Science Pharmaceutical Research<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors SEATTLE&#8211;(BUSINESS WIRE)&#8211; Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine\u2019s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. \u201cI\u2019m delighted to welcome Natasha to Alpine Immune Sciences\u2019 Board at this important moment in our company\u2019s history, as we build on our strategic partnership with AbbVie and leverage Alpine\u2019s financial strength to further advance our development pipeline,\u201d said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. \u201cI look forward to benefiting from Natasha\u2019s extensive experience &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398151","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors SEATTLE&#8211;(BUSINESS WIRE)&#8211; Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine\u2019s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. \u201cI\u2019m delighted to welcome Natasha to Alpine Immune Sciences\u2019 Board at this important moment in our company\u2019s history, as we build on our strategic partnership with AbbVie and leverage Alpine\u2019s financial strength to further advance our development pipeline,\u201d said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. \u201cI look forward to benefiting from Natasha\u2019s extensive experience &hellip; Continue reading &quot;Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T13:03:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors\",\"datePublished\":\"2020-12-11T13:03:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/\"},\"wordCount\":831,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/\",\"name\":\"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-11T13:03:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors - Market Newsdesk","og_description":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors SEATTLE&#8211;(BUSINESS WIRE)&#8211; Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune\/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine\u2019s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. \u201cI\u2019m delighted to welcome Natasha to Alpine Immune Sciences\u2019 Board at this important moment in our company\u2019s history, as we build on our strategic partnership with AbbVie and leverage Alpine\u2019s financial strength to further advance our development pipeline,\u201d said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. \u201cI look forward to benefiting from Natasha\u2019s extensive experience &hellip; Continue reading \"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-11T13:03:33+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors","datePublished":"2020-12-11T13:03:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/"},"wordCount":831,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/","name":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-11T13:03:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201211005057r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alpine-immune-sciences-appoints-natasha-hernday-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398151"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398151\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}